Tender Results of Nhs England

NHS National Generic Pharmaceuticals Wave 14a-Invitation to offer for NHS National Generic Pharmaceuticals Wave 14a
Offer reference number: CM/PHG/22/5657/03
Period of framework agreement: The total maximum duration of the framework agreement to be no more than 24 months with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 48 months.
Potential periods of call-offs under the framework agreement:
Housekeeping Products (Hospital Only): CESW 01/02...

National Framework Agreement for Adalimumab Injection 1 April 2023-Lot 1 - CM/PHR/22/5660/01 - NHS Framework Agreement for the supply of Adalimumab Injection to South of England. Period of framework: 1 April 2023 to 31 August 2024 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months

NHS North of England Branded Medicines Tranche A & Annual Tranche-Lot 1 - CM/PHR/20/5606/01 - NHS Framework for North of England Branded Medicines - Tranche A. Period of framework: 1 March 2023 to 28 February 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months

NHS National Generic Pharmaceuticals Wave 14a-Invitation to offer for NHS National Generic Pharmaceuticals Wave 14a Offer reference number: CM/PHG/22/5657 Period of framework agreement: The total maximum duration of the framework agreement to be no more than 24 months with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 48 months. Potential periods of call-offs under the framework agreement: Hospital Only Products: DLN & DNW 01/02/2023 - 31/01/2025 (24 Months)

UK Domestic Plasma Fractionation Service-NHS Agreement for the Provision of UK Plasma Fractionation Services and Supply of Plasma-derived Products to the NHS

NHS Framework for Midland & East Branded Medicines, Tranche B & Annual Tranche-Lot 1 - CM/PHR/20/5608/01 - NHS Framework for Midlands and East Branded Medicines - Tranche B. Period of framework: 1 March 2023 to 28 February 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months

NHS Framework for Midland & East Branded Medicines, Tranche B & Annual Tranche-NHS Framework for Midlands and East Branded Medicines - Tranche B and Annual Tranche. Offer reference number: CM/PHR/20/5608 CM/PHR/20/5608/01 - NHS Framework for Midlands and East Branded Medicines - Tranche B. Period of framework: 1 March 2023 to 28 February 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months CM/PHR/20/5608/02 - NHS Framework for Midlands and East Branded Medicines - Annual Tra...

NHS National Framework Agreement for the supply of Eculizumab-NHS National Framework Agreement for the supply of Eculizumab Offer reference number: CM/PHR/22/5659 Period of framework: 01 January 2023 to 31 December 2023 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months

National Framework Agreement for Adalimumab Injection 1 April 2023-Project Title: NHS National Framework Agreement for the supply of Adalimumab Injection commencing 1 April 2023 Offer reference number: CM/PHR/22/5660 CM/PHR/22/5660/01 - NHS Framework Agreement for the supply of Adalimumab Injection to South of England. Period of framework: 1 April 2023 to 31 August 2024 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months CM/PHR/22/5660/02 - NHS Framework Agreement for the...

GRAIL Digital Infrastructure to support Galleri testing-In December 2020, NHS England entered into a commercial agreement with GRAIL to test and rapidly deploy their Galleri Multi-Cancer Early Detection (MCED) test. The agreement commits NHSE to deploy 1,000,000 Galleri tests across the years 2024 and 2025 on the condition that the interim results of the trial meet certain strict conditions. This programme has been termed the ‘Interim Implementation Pilot’. The success of the 2024 programme will be dependent on a delivery model that is underpinned by...